The role of advanced molecular diagnostics for infectious disease continues to grow – not only are these assays moving into the clinic, but they are being used for infection surveillance and outbreak control, appearing in the pharmacy, and continuing to improve care in resource-limited settings. Cambridge Healthtech Institute’s 5th Annual Molecular Diagnostics for Infectious Disease conference program will feature the latest in NGS and metagenomics, the latest regulatory and reimbursement challenges, and updates in the public health sphere. We’ll further examine the role of host response vs. pathogen detection in the clinic, the potential for microbiome analysis, and other novel approaches to infectious disease diagnosis. Special attention will be paid to antimicrobial resistance, from the clinical challenges to the emerging technologies, and novel technologies being developed specifically for resource-limited settings. We will also address the state of the industry from the point-of-view of numerous stakeholders: industry, regulatory, investment, technology, and clinical.

Final Agenda

 

Sunday, March 1

2:00 - 5:00 pm Afternoon Short Courses*

*Separate registration required

5:30 - 8:30 Dinner Short Courses*

*Separate registration required

Monday, March 2

8:00 - 11:00 am Morning Short Courses*

*Separate registration required

10:30 Conference Program Registration Open

FEATURED PANEL DISCUSSION: STATE OF THE POINT-OF-CARE AND INFECTIOUS DISEASE INDUSTRY

11:45 Organizer’s Opening Remarks

Kaitlin Searfoss Kelleher, Conference Producer, Cambridge Healthtech Institute

11:50 Chairperson’s Remarks

David Cavanaugh, Partner, DeciBio

11:55 Leading the Pack: The Strategic Revamp POC Dx Needs before Disrupting MDx

Clinical adoption and real-world use of point-of-care diagnostic (POC Dx) technologies have fallen short of their hype and promise. The field has become increasingly crowded, with hundreds of players narrowing the runway for each company to carve out differentiated market opportunities and strategies. Disruption of the larger MDx market will require POC Dx companies to create “winning strategies” by establishing competitive differentiation from one another, driving successful adoption and implementation, and navigating regulatory and reimbursement hurdles.

Cavanaugh_DavidModerator: David Cavanaugh, Partner, DeciBio


Stein_EsterPanelists: Ester Stein, Director, Corporate Reimbursement, Government Affairs, Abbott Laboratories


Abel_GyorgyGyorgy Abel, MD, PhD, Director, Molecular Diagnostics, & Clinical Chemistry/Immunology, Division of Pathology and Laboratory Medicine, Lahey Hospital & Medical Center, Burlington, MA


Martin_TrevorTrevor Martin, PhD, Co-Founder and CEO, Mammoth Biosciences


Rooke_JennyJenny Rooke, PhD, Managing Director, Genoa Ventures

 

 

 

Bothwell_BryanBryan Bothwell, Director, Strategy and Business Development, Qorvo Biotechnologies

 

 

 

 

 

Joseph San Filippo, PhD, Director, Business Development, Roche Molecular Solutions

 

12:55 pm Session Break

1:05 LUNCHEON PRESENTATION I: Karius Microbial Cell-free DNA for Non-invasive Identification & Prediction of Infections in Immunocompromised Patients

Blauwkamp_TimTim Blauwkamp, PhD, CSO, Karius

Immunocompromised patients are vulnerable to a wide variety of infections. The Karius Test uses next-generation sequencing of microbial cell-free DNA in blood to help diagnose infections throughout the body, offering a non-invasive alternative with higher diagnostic yield than conventional methods.  We present current applications in clinical practice and describe potential future applications in predicting infections in high-risk immunocompromised patients.


1:35 LUNCHEON PRESENTATION II: Commercialization of an IVD in a Changing Global Environment

Stephenson_LynnLynn Stephenson, PhD, Marketing Manager, Dx Manufacturing & OEM, MilliporeSigma

Changes in international standards and regulations have created challenges and roadblocks to the commercialization of diagnostic devices. The choice of a contract manufacturing (CM) partner with the expertise to provide guidance and manufacturing capabilities is one strategy diagnostics companies can use to mitigate risk.  A well-chosen CM partner can accelerate the commercialization process by anticipating potential roadblocks.  In this session, we will discuss best practices and key considerations for vetting contract manufacturing partners.

2:05 Session Break

NGS AND CLINICAL METAGENOMICS

2:20 Chairperson’s Remarks

Nathan Ledeboer, PhD, Professor and Vice Chair, Pathology and Medical Director, Medical College of Wisconsin

2:25 The Promise of Culture-Free Microbiology: Are Clinical Labs Ready and Will Metagenomics Deliver on the Promise?

Ledeboer_NathanNathan Ledeboer, PhD, Professor and Vice Chair, Pathology and Medical Director, Medical College of Wisconsin

Next Generation Sequencing offers the potential to interrogate clinical specimens for the presence of infectious diseases in a completely unbiased manner. However, significant challenges confront clinical microbiology laboratories attempting to implement metagenomics using traditional clinical workflows. This presentation will discuss targeted implementation of a metagenomics assay for the detection of mycobacteria and nocardia from clinical specimens.

2:55 Clinical Metagenomic Sequencing – New Technologies and Advances in the Near Future

Chiu_CharlesCharles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases, Director, UCSF-Abbott Viral Diagnostics and Discovery Center, Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine

Metagenomic next-generation sequencing (mNGS) is a potentially game-changing technology for infectious disease diagnosis as it enables detection of nearly all pathogens in a single assay. This approach has been made feasible by the rapid advances in sequencing technology, bioinformatics analysis, and reference databases. In this talk I will discuss how we overcome challenges in development and validation of an mNGS-based assay in a CLIA laboratory regulatory environment. I will discuss efforts to expand clinical mNGS validation and testing to new body fluids, as well as new transformative tech.

3:25 Towards Clinical Implementation of Rapid Metagenomics for the Diagnosis of Nosocomial Pneumonia

OGrady_JustinJustin O’Grady, PhD, Associate Professor, Quadram Institute Bioscience

The rise in antimicrobial resistance (AMR) is predicted to cause 10 million deaths per year by 2050 unless steps are taken to prevent this looming crisis. Microbiological culture is the gold standard for the diagnosis of bacterial/fungal pathogens and antimicrobial resistance and takes 48 hours or longer. Hence, antibiotic prescriptions are rarely based on a definitive diagnosis and patients often receive inappropriate treatment. Rapid diagnostic tools are urgently required to guide appropriate antimicrobial therapy, thereby improving patient outcomes and slowing the development of AMR. In this talk, I will discuss the application of rapid (~6hr) clinical metagenomics for the diagnosis of hospital-acquired and ventilator-associated pneumonia.

SerImmune 3:55 Advanced Serology and Immune Status Reports Powered by the Human Immunity Map

Patrick Daugherty, PhD, CSO and Founder, Serimmune, Inc.

While clinical use of antibody serology for infectious disease generally has been limited to targeted assays for just a few organisms, numerous clinical scenarios could benefit from a broad view of serological immunity.  Combining high diversity peptide display libraries, next-generation sequencing, and custom bioinformatics, we developed serum epitope repertoire analysis (SERA) to map circulating antibody specificities to their antigens and reveal one’s immune history.  Bioinformatic analysis of the resulting digital immune record enables effectively unlimited multiplexing of epitope-specific antibody assays.  We analyzed the serological antibody repertoires from more than 10,000 individuals reflecting diverse disease states including viral, bacterial, parasitic and fungal infections, autoimmunity, and cancer to build a Human Immunity Map (HIMap).  We demonstrate the utility of SERA coupled with HIMap to measure IgG and IgM serostatus for Lyme along with 50 other infectious and autoimmune markers in 1500 individuals referred for Lyme disease testing.  Our results suggest that SERA has the potential to substantially increase diagnostic yields, thereby circumventing costly and burdensome diagnostic odysseys.

Ubiquitome_NoTagline 4:10 COVID-19 Could Be Identified in Minutes via Mobile Technology

Pickering_PaulPaul Pickering, PhD, Chairman & CEO, Ubiquitome Limited

Fast testing during viral outbreaks, such as the coronavirus COVID-19, could assist preventing its spread. Ubiquitome will present RT-PCR data, from its proprietary Liberty16 mobile molecular detection system, covering both animal and human health. Results are reported in real time via Ubiquitome’s iPhone app interface for dynamic outbreak response.

4:25 Refreshment Break and Transition to Plenary Keynote


PLENARY KEYNOTE SESSION

(please see Keynote pages for details)

4:35 Welcome Remarks

Cindy Crowninshield, RDN, LDN, HHC, Executive Event Director, Cambridge Healthtech Institute

4:45 PLENARY KEYNOTE INTRODUCTION

Thomas Westerling-Bui, PhD, Senior Scientist, Regional Business Development, Aiforia

5:00 PLENARY KEYNOTE PRESENTATION: High-Performance Medicine

Eric Topol, MD, Founder and Director, Scripps Research Translational Institute (SRTI); Author, Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again

 

 

 

 

6:00 Grand Opening Reception in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

7:30 End of Day

 

Tuesday, March 3

7:30 am Registration Open and Morning Coffee

FEATURED SESSION: ADDRESSING ANTIMICROBIAL RESISTANCE THROUGH THE NIH-BARDA GRAND CHALLENGE

8:00 Organizer’s Remarks

Kaitlin Searfoss Kelleher, Conference Producer, Cambridge Healthtech Institute

MeMed_New 8:05 Chairperson’s Remarks

Gottlieb_TanyaTanya Gottlieb, PhD, Vice President, Scientific Affairs, MeMed

 

 

 

8:10 Point-of-Care Diagnostics for Antibiotic Stewardship in the Hospital and Beyond

May_LarissaLarissa May, MD, MSPH, MSHS, Professor and Director of ED and Outpatient Antibiotic Stewardship, Emergency Medicine, UC Davis Health

This presentation will focus on opportunities for expanding POC diagnostics for management of infectious diseases in the ED and other areas in the health system. We will demonstrate successful implementation, lessons learned, and regulatory and practical considerations.

8:35 Geospatial “Hot Spots” in Need of Rapid Point-of-care Diagnostics for Highly Infectious Threats and Antimicrobial Resistance

Kost_GeraldGerald Kost, MD, PhD, MS, FAACC, Director, Point-of-Care Testing Center for Teaching and Research (POCT-CTR), Emeritus Professor, School of Medicine, University of California, Davis

We will develop a framework for deploying novel point-of-care technologies that detect antimicrobial resistance. Hot spots occur across world locations no longer limited geospatially. We can integrate geoscience tools and point-of-care testing to quickly, directly, and efficiently detect microbial and viral threats. Spatial patterns of resistance will allow us to target therapy cost-effectively.

9:00 PANEL DISCUSSION: Addressing Antimicrobial Resistance Through Public-Private Partnerships and the NIH-BARDA Grand Challenge

Antimicrobial resistance represents a growing public health concern, leading to BARDA and the NIH working with private companies to develop novel diagnostics. The NIH-BARDA Grand Challenge has charged participants with developing innovative and novel rapid diagnostic tests to identify resistant bacteria or to distinguish between viral and bacterial infections to reduce over-prescription of antibiotics. Two of the five finalists will present their work and the challenges their technologies address. We will also hear from a company collaborating directly with BARDA to advance and commercialize their assay.

Kost_GeraldModerator: Gerald Kost, MD, PhD, MS, FAACC, Director, Point-of-Care Testing Center for Teaching and Research (POCT•CTR), Emeritus Professor, School of Medicine, University of California, Davis


Tsalik_EphraimPanelists: Ephraim Tsalik, MD, MHS, PhD, Founder, Predigen, Inc.


Schoolnik_GaryGary Schoolnik, Director, Medical Affairs, Click Diagnostics


Sweeney_TimTimothy Sweeney, MD, PhD, CEO, Inflammatix


 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

ADVANCES IN SEQUENCING TECHNOLOGY AND ITS ROLE IN MODERN INFECTIOUS DISEASE DIAGNOSIS

10:40 Improving Openness, Reproducibility and Scalability in Microbial Genomics and Bioinformatics for Public Health

MacCannell_DuncanDuncan MacCannell, PhD, CSO, Office of Advanced Molecular Detection, Centers for Disease Control and Prevention

Advances in sequencing technology have fundamentally changed laboratory approaches to infectious disease diagnostics, pathogen characterization, molecular epidemiology and surveillance. Operationalizing these technologies requires significant investments in bioinformatics infrastructure and workforce. This presentation will discuss efforts to improve the openness, reproducibility and scalability of microbial genomics applications across a range of public health laboratory settings.

11:10 NEW: CO-PRESENTATION: COVID-19 Coronavirus Emergency Response Test Development Utilizing Co-Diagnostics CoPrimer TM Technology

Egan_DwightDwight Egan, CEO, Co Diagnostics


Christensen_MasenMasen Christsensen, Senior Design Engineer, Co Diagnostics

Our CoPrimer technology allows for rapid test development with sharp sensitivity and specificity. CoPrimers have been shown to virtually eliminate the formation of primer-dimers reducing false positives/negatives. The company’s mission is to provide state of the art diagnostics at affordable prices to the people and nations who need them the most. We specialize in infectious diseases, Agribio & tests for mosquitos to aid in vector control. Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Insilixa 11:40 Semiconductor Biochip System for Rapid and High-multiplex Identification, Quantification, and Genotyping of Pathogens  

Kirsten Johnson, PhD, Research and Development Senior Manager, InSilixa, Inc.

The emergence of pathogens resistant to antimicrobials is a growing worldwide health crisis. To curtail antimicrobial misuse, InSilixa has developed a fully integrated, miniaturized semiconductor biochip system that can rapidly identify pathogens, quantify microbial load and determine the drug resistance profile of up to 250 sequences simultaneously. Applications developed on this platform include an upper respiratory pathogen panel, antimicrobial resistance genotyping of M. tuberculosis, and viral load quantification and genotyping of HIV-1.

12:10 pm Session Break

1:20 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

2:00 Breakout Discussions in the Exhibit Hall (please click here for details)

3:00 Transition to Keynote Session

KEYNOTE SESSION

3:15 Organizer’s Remarks

Christina Lingham, Executive Director, Conferences and Fellow, Cambridge Healthtech Institute

3:20 Keynote Introduction

Mallory_AllisonAllison Mallory, PhD, Director, R&D Molecular Biology, Stilla Technologies

 

 

 

3:35 What Does the New Era of Genomic Medicine Look Like? Effects on Patient Care, Therapeutics, and Diagnostics

20 years after the completion of the first draft of the Human Genome Project, there is compelling evidence of genomics delivering the rich promise of precision medicine. There have been major advances in the throughput and affordability of genome sequencing, enhanced tools for genome analysis and interpretation, new paradigms for therapeutics and strong signs of clinical benefit using genome editing. But major challenges remain. In this special plenary roundtable, three established pioneers of genomic medicine – David Haussler, Stephen Kingsmore, and Liz Worthey – offer their insights on the extraordinary advances in genomic medicine over the past 1-2 decades and share their hopes and concerns for the future of our field.

Davies_KevinModerator: Kevin Davies, PhD, Executive Editor, The CRISPR Journal, Mary Ann Liebert, Inc.


Kingsmore_StephenPanelists: Stephen Kingsmore, MD, DSc, President/CEO, Rady Children’s Institute for Genomic Medicine


Haussler_DavidDavid Haussler, PhD, Investigator, Howard Hughes Medical Institute; Distinguished Professor, Biomolecular Engineering, University of California, Santa Cruz; Scientific Director, UC Santa Cruz Genomics Institute; Scientific Co-Director, California Institute for Quantitative Biosciences (QB3)


Worthey_LizElizabeth Worthey, PhD, Director, Genomic Medicine, University of Alabama, Birmingham School of Medicine


4:50 Spring Fling Celebration in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

6:00 End of Day

 

6:30 - 9:30 Dinner Short Courses*

*Separate registration required

Wednesday, March 4

6:45 am Registration Open

7:00 BREAKFAST PANEL DISCUSSION: The Time is NOW: Creating Meaningful Change for Women in the Workplace (Sponsorship Opportunity Available)

(please see Women in Science page for details)

Toft_RobinModerator: Robin Toft, Author of WE CAN, The Executive Woman’s Guide to Career Advancement; Founder and Chairman, Toft Group Executive Search


Samuels_CamillePanelists: Camille Samuels, MBA, Partner, Venrock


Hastings_PaulPaul Hastings, President and CEO, Nkarta Therapeutics, Inc


Wright_TerryTeresa L. Wright, MD, Staff Physician, Medicine, San Francisco Veterans Administration


UTILIZING ADVANCED ANALYTICS, ALGORITHMS, AND MACHINE LEARNING IN DIAGNOSIS

8:00 Organizer’s Remarks

Kaitlin Searfoss Kelleher, Conference Producer, Cambridge Healthtech Institute

8:05 Chairperson’s Remarks

Jennifer Dien Bard, PhD D(ABMM), Director, Microbiology and Virology, Pathology and Laboratory Medicine, Children’s Hospital Los Angeles; University of Southern California

8:10 Machine Learning to Detect Antibiotic Resistance: Progress and Challenges

Greenberg_DaveDavid Greenberg, MD, Associate Professor, Microbiology and Internal Medicine, University of Texas Southwestern

This talk will discuss the use of next generation sequencing approaches for predicting antibiotic resistance. It will focus on the application and development of bioinformatic pipelines to help predict resistance accurately without the need for phenotypic testing. Examples of success as well as challenges in the field will be explored.

MeMed_New 8:40 The Power of Bioconvergence: MeMed BV™, Using the Host Response to Distinguish between Bacterial and Viral Infections

Sweeney_FredFrederic Sweeney, PhD, Chief Business Development Officer, MeMed Diagnostics Ltd.

At the crossroad between medical evidence, biochemistry, engineering and machine learning, the MeMed team has developed a powerful platform to discover, develop, validate and commercialize new diagnostics tools.  MeMed’s first test (MeMedBV™) relied on a machine learning approach of discovery and validation of over 100,000 biomarker combinations where the best performing combination computationally integrates three circulating host proteins into a score with >90% accuracy which has been validated in multiple double-blind international studies.

9:10 Developing an mRNA-Based Panel for Pre-Symptomatic Detection of Sepsis

Wang_KaiKai Wang, PhD, Principal Scientist, Institute for Systems Biology

Using longitudinal samples from patients undergoing elective surgery, we identified a blood mRNA-based panel that could diagnose sepsis 2 to 3 days prior to the onset of clinical symptoms, allowing for much earlier therapeutic intervention. The panel was optimized using a biological function-based algorithm to reduce the number of features in the assay without affecting the performance. The diagnostic performance of the panel was validated with validation cohort.

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

CASES IN MOLECULAR DIAGNOSTICS FOR INFECTIOUS DISEASE

10:40 CO-PRESENTATION: From Bench to Bedside: Real-World Cases in Molecular Diagnostics for Infectious Diseases

Dien_Bard_JenniferJennifer Dien Bard, PhD D(ABMM), Director, Microbiology and Virology, Pathology and Laboratory Medicine, Children’s Hospital Los Angeles; University of Southern California


Butler_Wu_SusanSusan Butler-Wu, PhD, D(ABMM), Associate Professor of Clinical Pathology, Keck School of Medicine, University of Southern California, Director of Clinical Microbiology, LAC+USC Medical Center

Development of molecular assays has increased exponentially in the past decade and have revolutionized testing in the clinical laboratories. But how are tests being offered and reported in the laboratory? Further, how are results being interpreted by providers? This session will provide adult and pediatric case examples of the pros and woes of molecular diagnostics for infectious diseases. An interactive discussion on current and future directions of diagnostic assays will follow.

Lucira_Health 12:10 pm Improving Influenza Outcomes Through OTC Molecular Diagnostics

Frank MyersFrank Myers, PhD, Director of Engineering, Lucira Health

Nearly 90% of patients with influenza do not seek medical treatment within the 48 hour window necessary for antiviral treatment. Lucira Health is developing an over-the-counter influenza diagnostic which better fits patient relief-seeking habits at symptom onset, enabling more timely and effective access to antiviral treatment and improved flu outcomes.

12:25 Sponsored Presentation (Opportunity Available)

12:40 Session Break

12:50 Precision Health Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall with Last Chance Poster Viewing, Speed Networking, Book Signing, and Meetup Group

FEATURED SESSION: IMPLEMENTING POINT-OF-CARE DIAGNOSTICS IN RESOURCE-LIMITED SETTINGS

2:00 Chairperson’s Remarks

Michael Loeffelholz, Senior Director, Medical Affairs, Cepheid

2:05 Challenges and Opportunities in Resource-Limited Settings for POC IVD Manufacturers

Loeffelholz_MichaelMichael Loeffelholz, Senior Director, Medical Affairs, Cepheid

The impact of point-of-care technologies in resource-limited settings is profound, but the development, funding, and implementation of these technologies is not always easy. There are several challenges and opportunities for POC IVD manufacturers in resource-poor settings: technology, development, regulatory, cost considerations, to name a few. We’ll examine the industry and business perspective, as well as the clinical implementation and, most importantly, the impact these point-of-care technologies have on patient care.

2:50 NEW: Point-of-Care Testing: Bringing the Laboratory to the Patient in Low- and Middle-Income Country Settings

Klausner_JeffreyJeffrey Klausner, MD, MPH, Professor of Medicine and Public Health, David Geffen School of Medicine, University of California, Los Angeles

I will review studies across three continents demonstrating the acceptability, feasibility, and value of point-of-care diagnostic testing for sexually transmitted infections in pregnant women.

3:35 Close of Conference

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag


Premier Sponsors

AWS
Asuragen

Discovery-Life-Sciences

L7-informatics

NeoGenomics

Redbud-Labs

Roche

Stilla


ximedica